Skip to content
Peptigraph home

How ARA-290 Works: Mechanism and Pharmacology

How ARA-290 works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.

Medical review pendingEPO-derived peptideUpdated
Class
EPO-derived peptide
FDA status
Not approved
research chemical
Routes studied
intravenous; subcutaneous, self-administered; intraperitoneal
Half-life
~2 min
plasma (route not stated in abstract), in people · Pharmacology & therapeutics 2015, PMID 25728128

How long it acts

Half-life values from FDA labels and published studies, by route. Animal values are labelled and do not describe people.

ARA-290 half-life by route
RouteHalf-lifeMeasured inSource
plasma (route not stated in abstract)~2 minPeoplePharmacology & therapeutics 2015, PMID 25728128

The receptor it targets

ARA 290 is described as a peptide designed to activate the innate repair receptor, which the authors say arrests injury and initiates protection, anti-inflammation and healing.[2]

The innate repair receptor is a heteromer of the erythropoietin receptor and the beta-common receptor (CD131), as distinct from the EPOR homodimer that drives red cell production.[3]

The review explains that the innate repair receptor is typically not expressed in normal tissue but is induced rapidly by injury or inflammation.[1]

Evidence that the receptor matters (animals)

In mice lacking the beta-common receptor, ARA290 had no effect on pain behaviour, while it worked in normal mice, which supports receptor dependence in this mouse model.[4]

In activated mouse macrophages, cibinetide's anti-inflammatory effect depended on CD131 and JAK2 and ran through inhibition of the NF-kB subunit p65.[3]

In rats with autoimmune encephalomyelitis, ARA290 shifted T-cell polarisation towards Th2 and regulatory T cells and away from Th1 and Th17 cells.[5]

What happens in people

In a phase 2b sarcoidosis trial, cibinetide increased small nerve fibre abundance in the cornea and skin, which the authors called consistent with a disease modifying effect.[6]

In healthy volunteers given ARA290, neural responses to happy faces were lower in the fusiform gyrus of the brain.[7]

Common questions

How long does ARA-290 act in the body?

The half-life values we found are ~2 min (plasma (route not stated in abstract)). A half-life is how long the amount in the body takes to fall by half; it is not the same as how long an effect lasts.

How does ARA 290 work?

It is designed to activate the innate repair receptor, a receptor complex that mediates tissue protection.[8]

More on ARA-290

Sources

  1. 1Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.Pharmacology & therapeutics · 2015PMID 25728128Accessed 2 Oct 2026
  2. 2Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.Molecular medicine (Cambridge, Mass.) · 2012PMID 23168581Accessed 2 Oct 2026
  3. 3Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.Scientific reports · 2017PMID 29026145Accessed 2 Oct 2026
  4. 4ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.Anesthesiology · 2011PMID 21873879Accessed 2 Oct 2026
  5. 5Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat.Journal of neuroimmunology · 2014PMID 24518674Accessed 2 Oct 2026
  6. 6Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.Investigative ophthalmology & visual science · 2017PMID 28475703Accessed 2 Oct 2026
  7. 7Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015PMID 26431906Accessed 2 Oct 2026
  8. 8ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Molecular medicine (Cambridge, Mass.) · 2015PMID 25387363Accessed 2 Oct 2026

Found an error? Report a correction.